Edition:
India

Cue Biopharma Inc (CUE.OQ)

CUE.OQ on NASDAQ Stock Exchange Capital Market

16.16USD
25 Sep 2020
Change (% chg)

$0.94 (+6.18%)
Prev Close
$15.22
Open
$15.12
Day's High
$16.34
Day's Low
$15.12
Volume
78,129
Avg. Vol
145,106
52-wk High
$31.67
52-wk Low
$6.95

Latest Key Developments (Source: Significant Developments)

Cue Biopharma Appoints Kerri-Ann Millar As CFO
Tuesday, 25 Aug 2020 

Aug 24 (Reuters) - Cue Biopharma Inc ::CUE BIOPHARMA - ON AUGUST 21, KERRI-ANN MILLAR WAS APPOINTED CFO OF CO.  Full Article

Cue Biopharma Announces Clinical Trial Collaboration Agreement With Merck
Monday, 20 Apr 2020 

April 20 (Reuters) - Cue Biopharma Inc ::CUE BIOPHARMA ANNOUNCES CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK TO EVALUATE CUE-101 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) AS FIRST-LINE TREATMENT FOR HPV+ RECURRENT/METASTATIC HEAD AND NECK CANCER.CUE BIOPHARMA INC - CUE BIOPHARMA WILL CONDUCT A PHASE 1 STUDY, KEYNOTE-A78.CUE BIOPHARMA INC - KEYNOTE-A78 WILL BE CONDUCTED IN PARALLEL WITH ONGOING PHASE 1 MONOTHERAPY STUDY OF CUE-101 POST FIRST-LINE TREATMENT.CUE BIOPHARMA - EARLY MONOTHERAPY PK DATA FROM FIRST TWO DOSING COHORTS DEMONSTRATES DOSE-RELATED DRUG EXPOSURE CONSISTENT WITH PRECLINICAL MODELING.CUE BIOPHARMA INC - CUE BIOPHARMA EXPECTS TO REPORT INITIAL PHARMACODYNAMIC DATA FROM PHASE 1 MONOTHERAPY PORTION OF STUDY IN FIRST HALF OF 2020.  Full Article

Cue Biopharma Files For Common Stock Offering Of Up To $35.0 Mln - SEC Filing
Saturday, 28 Mar 2020 

March 27 (Reuters) - Cue Biopharma Inc ::CUE BIOPHARMA INC FILES FOR COMMON STOCK OFFERING OF UP TO $35.0 MILLION - SEC FILING.  Full Article

Cue Biopharma Reports Qtrly Loss Per Share Of $0.37
Wednesday, 18 Mar 2020 

March 17 (Reuters) - Cue Biopharma Inc ::CUE BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.QTRLY COLLABORATION REVENUE OF ABOUT $1.0 MILLION VERSUS $0.3 MILLION.QTRLY LOSS PER SHARE $0.37.Q4 EARNINGS PER SHARE VIEW $-0.45, REVENUE VIEW $873000.00 -- REFINITIV IBES DATA.  Full Article

Cue Biopharma Reports Third Quarter 2019 Financial Results
Wednesday, 13 Nov 2019 

Nov 12 (Reuters) - Cue Biopharma Inc ::CUE BIOPHARMA REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.CUE BIOPHARMA INC QTRLY LOSS PER SHARE $0.31.CUE BIOPHARMA INC QTRLY COLLABORATION REVENUE $984 MILLION VERSUS $449 MILLION.  Full Article

Cue Biopharma Qtrly Loss Per Share $0.31
Wednesday, 13 Nov 2019 

Nov 12 (Reuters) - Cue Biopharma Inc ::CUE BIOPHARMA REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.CUE BIOPHARMA INC QTRLY LOSS PER SHARE $0.31.CUE BIOPHARMA INC QTRLY COLLABORATION REVENUE $984,000 VERSUS $449,000 .  Full Article

Cue Biopharma Announces FDA Acceptance Of Ind For Lead Immuno-Oncology Candidate, Cue-101, In Treatment Of Hpv-Driven Cancers
Thursday, 16 May 2019 

May 16 (Reuters) - Cue Biopharma Inc ::CUE BIOPHARMA ANNOUNCES FDA ACCEPTANCE OF IND FOR LEAD IMMUNO-ONCOLOGY CANDIDATE, CUE-101, IN TREATMENT OF HPV-DRIVEN CANCERS.CUE BIOPHARMA INC - INITIATION OF FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL FOR MONOTHERAPY DOSE ESCALATION.CUE BIOPHARMA INC - EARNS $2.5 MILLION MILESTONE FOR IND ACCEPTANCE FROM PARTNER LG CHEM LIFE SCIENCES.  Full Article

BRIEF-Cue Biopharma Entered Into Second Amendment To License Agreement With Mil 21E Dated Jan. 19, 2018

* CUE BIOPHARMA- ON JUNE 24, ENTERED INTO SECOND AMENDMENT TO LICENSE AGREEMENT TO ITS LICENSE AGREEMENT WITH MIL 21E, LLC DATED JAN. 19, 2018